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A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra 
Pars Compacta in Parkinson’s Disease 
ABSTRACT 
Background: Parkinson’s disease (PD) is caused by the progressive loss of dopaminergic cells 
in substantia nigra pars compacta (SNc). The root cause of this cell loss in PD is still not 
decisively elucidated. A recent line of thinking traces the cause of PD neurodegeneration to 
metabolic deficiency. Due to exceptionally high energy demand, SNc neurons exhibit a higher 
basal metabolic rate and higher oxygen consumption rate, which results in oxidative stress. 
Recently, we have suggested that the excitotoxic loss of SNc cells might be due to energy 
deficiency occurring at different levels of neural hierarchy. Levodopa (LDOPA), a precursor 
of dopamine, which is used as a symptom-relieving treatment for PD, leads to outcomes that 
are both positive and negative. Several researchers suggested that LDOPA might be harmful 
to SNc cells due to oxidative stress. The role of LDOPA in the course of PD pathogenesis is 
still debatable.  
New Method: We hypothesize that energy deficiency can lead to LDOPA-induced toxicity 
(LIT) in two ways: by promoting dopamine-induced oxidative stress and by exacerbating 
excitotoxicity in SNc. We present a multiscale computational model of SNc-striatum system, 
which will help us in understanding the mechanism behind neurodegeneration postulated above 
and provides insights for developing disease-modifying therapeutics. 
Results: It was observed that SNc terminals are more vulnerable to energy deficiency than SNc 
somas. During LDOPA therapy, it was observed that higher LDOPA dosage results in 
increased loss of somas and terminals in SNc. It was also observed that co-administration of 
LDOPA and glutathione (antioxidant) evades LDOPA-induced toxicity in SNc neurons. 
Comparison with Existing Methods: Our proposed multiscale model of SNc-striatum system 
is first of its kind, where SNc neuron was modelled at biophysical level, and striatal neurons 
were modelled at spiking level. 
Conclusions: We show that our proposed model was able to capture LDOPA-induced toxicity 
in SNc, caused by energy deficiency. 
Keywords: Parkinson’s disease; Levodopa; Dopamine; Substance P; Striatum; 
Substantia nigra pars compacta; 
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1. INTRODUCTION 
Almost all neurodegenerative diseases have a characteristic loss of a certain special type of 
cells that are vulnerable to death due to metabolic deficiency (Fu et al., 2018; Muddapu et al., 
2020). Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc), which results in cardinal symptoms such as tremor, 
rigidity, bradykinesia and postural instability (Goldman and Postuma, 2014). The root cause of 
SNc cell loss in PD is still not decisively elucidated. Recently, a modeling study has been 
proposed where PD is described to be resulting from the metabolic deficiency in SNc 
(Muddapu et al., 2019). The vulnerable cells of SNc are projection neurons with large axonal 
arbors of complex morphologies, requiring a huge amount of energy to maintain information 
processing activities (Bolam and Pissadaki, 2012; Giguère et al., 2019; Muddapu et al., 2020; 
Pissadaki and Bolam, 2013). Due to huge energy requirements, SNc neurons exhibit higher 
basal metabolic rates and higher oxygen consumption rate, which result in oxidative stress 
(Pacelli et al., 2015). With the help of a computational model, Muddapu et al. (Muddapu et al., 
2019) have recently suggested that the excitotoxic loss of SNc cells might be due to energy 
deficiency occurring at different levels of neural hierarchy – systems, cellular and subcellular. 
Levodopa (LDOPA), a precursor of dopamine (DA), is used as a symptom-relieving 
treatment for PD (Poewe et al., 2010). The usage of LDOPA for PD is still debated due to its 
side-effects with long-term treatment (Fahn, 2005; Lipski et al., 2011; Thanvi and Lo, 2004). 
Several researchers suggested that LDOPA might be harmful to SNc cells by a mechanism that 
probably involves oxidative stress (Carvey et al., 1997; Pardo et al., 1995; Takashima et al., 
1999). However, several others proposed that LDOPA might not accentuate neurodegeneration 
of SNc neurons (Billings et al., 2019; Fahn, 2005; Fahn et al., 2004; Jenner and Brin, 1998) 
and sometimes acts a neuroprotective agent (Fahn, 2005; Schapira, 2008; Shimozawa et al., 
2019) or promote recovery of dopaminergic markers in the striatum (Murer et al., 1998, 1999). 
After several studies, it is still not clear why LDOPA is not toxic in case of nonparkinsonian 
human subjects and healthy animals and toxic in PD models of rodents (Agid, 1998; Fahn, 
1997; Lipski et al., 2011; Müller et al., 2004; Olanow and Obeso, 2011; Paoletti et al., 2019; 
Weiner, 2006; Ziv et al., 1997). The beneficial or toxic effects of LDOPA needs to be 
investigated with more thorough experiments performed at preclinical and clinical levels. 
In this paper, we investigate, using computational modelling, the hypothesis that 
LDOPA-induced toxicity can occur in two ways: by promoting DA-induced oxidative stress 
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(autoxidation-relevant) (Borah and Mohanakumar, 2010; Carvey et al., 1997; Melamed et al., 
1998; Pardo et al., 1995; Takashima et al., 1999; Walkinshaw and Waters, 1995) or by 
exacerbating excitotoxicity in SNc (autoxidation-irrelevant) (Blomeley et al., 2009; Blomeley 
and Bracci, 2008; Cheng et al., 1996; Pardo et al., 1993; Thornton and Vink, 2015), or by both 
the mechanisms which might be actually precipitated by energy deficiency. In order to 
investigate our hypothesis, we propose a multiscale computational model of L-DOPA-induced 
toxicity in SNc, which will help us in understanding the mechanism behind neurodegeneration 
due to LDOPA and gives insights for developing disease-modifying therapeutics. 
2. MATERIALS AND METHODS 
The proposed model of levodopa-induced toxicity (LIT) consists of the cortico-basal ganglia 
system. We model a part of the basal ganglia system comprising the following nuclei: SNc, 
Striatum, Subthalamic nucleus (STN), and Globus Pallidus externa (GPe). Within the SNc, we 
separately consider SNc soma (cell body) and SNc terminals (boutons) that make contact with 
striatal neurons. Within the striatum, we model D1-type receptor-expressing medium spiny 
neurons of two subtypes: 1) D1-MSNs that release GABA only (D1-MSN) (GABAergic only) 
and 2) D1-MSNs that release GABA and substance P, D1-MSN (GABAergic (G), and 
substance P (S)). In the cortex (CTX), the pyramidal neurons are modeled. Neurons in each 
nucleus are arranged as a two-dimensional lattice (Figure 1). All the simulations were 
performed by numerical integration using MATLAB (RRID: SCR_001622) with a time step 
of 0.1 𝑚𝑠. 
To implement energy deficiency conditions in the proposed model, the glucose and 
oxygen inputs were reduced to SNc cells. As the number of SNc neurons under energy 
deficiency increases, the dopaminergic tone to striatum decreases due to SNc terminal loss. 
The dopamine deficiency leads to lesser excitation of MSN neurons by pyramidal neurons in 
the cortex; as a result, SNc neurons get disinhibited. Disinhibition from MSN leads to 
overactivity of SNc neurons, which in turn results in SNc neurons degeneration due to 
excitotoxicity. 
In order to examine the LDOPA role in the degeneration of SNc neurons in PD, we 
administer LDOPA after a certain percentage of SNc neuronal loss due to energy deficiency 
and investigate how LDOPA changes the course of SNc cell loss. 
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2.1. Izhikevich (Spiking) Neuronal Model (STN, GPe, MSN, CTX) 
The Izhikevich neuronal models are capable of exhibiting biologically realistic firing patterns 
at a relatively low computational expense (Izhikevich, 2003). The proposed model of LIT 
consists of MSN (D1-MSN (G) and D1-MSN (GS)), STN, GPe, and CTX are modeled as 
spiking neuronal models using Izhikevich neuronal models arranged in the form of two-
dimensional lattices (Figure 1). Based on the anatomical data of the rat basal ganglia 
(Supplementary material-1), the neuronal population sizes in the model were selected 
(Arbuthnott and Wickens, 2007; Oorschot, 1996). The Izhikevich parameters for MSN were 
adapted from (Humphries et al., 2009);  for STN and GPe they were adapted from (Michmizos 
and Nikita, 2011) and (Mandali et al., 2015) respectively and those of CTX were adapted from 
(Izhikevich, 2003) are given in Supplementary material-2. The external bias current (𝐼𝑥) was 
adjusted to match the firing rate of nuclei with published data (Tripathy et al., 2015). 
The Izhikevich neuronal model of STN, GPe, CTX, and MSN consists of two variables, 
membrane potential (𝑣𝑥) and membrane recovery variable (𝑢𝑥): 
 𝐶𝑥 ∗
𝑑(𝑣𝑖𝑗
𝑥 )
𝑑𝑡
= 𝜑1 − 𝑢𝑖𝑗
𝑥 + 𝐼𝑖𝑗
𝑥 + 𝐼𝑖𝑗
𝑠𝑦𝑛
 (1) 
 
𝑑(𝑢𝑖𝑗
𝑥 )
𝑑𝑡
= 𝑎(𝑏 ∗ 𝜑2 − 𝑢𝑖𝑗
𝑥 ) (2) 
   
 
𝑖𝑓 𝑥 = 𝑆𝑇𝑁 𝑜𝑟 𝐺𝑃𝑒 𝑜𝑟 𝐶𝑇𝑋, 𝑡ℎ𝑒𝑛 
   
𝜑1 = 0.04(𝑣𝑖𝑗
𝑥 )2 + 5𝑣𝑖𝑗
𝑥 + 140 
 
𝜑2 = 𝑣𝑖𝑗
𝑥  
(3) 
   
 
𝑖𝑓 𝑥 = 𝑀𝑆𝑁, 𝑡ℎ𝑒𝑛 
   
𝜑1 = 𝑘
𝑥(𝑣𝑖𝑗
𝑥 − 𝑣𝑟
𝑥)(𝑣𝑖𝑗
𝑥 − 𝑣𝑡
𝑥) 
 
𝜑2 = (𝑣𝑖𝑗
𝑥 − 𝑣𝑟
𝑥) 
 
(4) 
   
Resetting: 
 𝑖𝑓  𝑣𝑖𝑗
𝑥 ≥ 𝑣𝑝𝑒𝑎𝑘
𝑥 , 𝑡ℎ𝑒𝑛          {
𝑣𝑖𝑗
𝑥 ← 𝑐
𝑢𝑖𝑗
𝑥 ← 𝑢𝑖𝑗
𝑥 + 𝑑
} (5) 
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where, 𝑣𝑖𝑗
𝑥 , 𝑢𝑖𝑗
𝑥 , 𝐼𝑖𝑗
𝑥 , and 𝐼𝑖𝑗
𝑠𝑦𝑛
 are the membrane potential, the membrane recovery variable, the 
external bias current, and total synaptic current received to neuron 𝑥 at the location (𝑖, 𝑗) 
respectively; 𝑣𝑡
𝑥 and 𝑣𝑟
𝑥 are the threshold and resting potentials respectively; 𝑘𝑥 is the 
membrane constant, 𝐶𝑥 is the membrane capacitance, {𝑎, 𝑏, 𝑐, 𝑑} are Izhikevich parameters; 
𝑣𝑝𝑒𝑎𝑘
𝑥  is the maximum membrane voltage set to neuron with 𝑥 being GPe or CTX or STN or 
MSN neuron. 
 
Figure 1: Model architecture of the levodopa-induced toxicity. CTX, cortex; STR, striatum; D1 MSN 
(GS), D1-type medium spiny neuron (GABAergic and Substance P); D1 MSN (G), D1-type medium 
spiny neuron (GABAergic); SNc, substantia nigra pars compacta; STN, subthalamic nucleus; GPe, 
globus pallidus externa; DA, dopamine. 
2.2. Biophysical (Conductance-based) Neuronal Model (SNc soma) 
The biophysical neuronal model of SNc in the proposed LIT model was adapted from 
(Muddapu and Chakravarthy, 2020). The detailed biophysical model of SNc neuron consists 
of soma and terminal which includes cellular and molecular processes such as ion channels 
(including active ion pumps, ion exchangers), calcium buffering mechanism (calcium-binding 
proteins, calcium sequestration organelles (such as endoplasmic reticulum, mitochondria)), 
energy metabolism (glycolysis and oxidative phosphorylation), DA turnover processes 
(synthesis, storage, release, reuptake, and metabolism), molecular pathways involved in PD 
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pathology (ROS formation and alpha-synuclein aggregation), and apoptotic pathways. The 
dynamics of SNc membrane potential (𝑣𝑆𝑁𝑐) is given as, 
 
𝑑(𝑣𝑖𝑗
𝑆𝑁𝑐)
𝑑𝑡
=
𝐹 ∗ 𝑣𝑐𝑦𝑡
𝐶𝑆𝑁𝑐 ∗ 𝒜𝑝𝑚𝑢
∗ [ 𝐽𝑚,𝑁𝑎 + 2 ∗ 𝐽𝑚,𝐶𝑎 + 𝐽𝑚,𝐾 + 𝐽𝑖𝑛𝑝] (6) 
 
where, 𝐹 is the Faraday’s constant, 𝐶𝑆𝑁𝑐 is the SNc membrane capacitance, 𝑣𝑐𝑦𝑡 is the cytosolic 
volume, 𝒜𝑝𝑚𝑢 is the cytosolic area, 𝐽𝑚,𝑁𝑎 is the sodium membrane ion flux, 𝐽𝑚,𝐶𝑎 is the 
calcium membrane ion flux, 𝐽𝑚,𝐾 is the potassium membrane ion flux, 𝐽𝑖𝑛𝑝 is the overall input 
current flux. The detailed information about the SNc neuron model was provided in (Muddapu 
and Chakravarthy, 2020). 
2.3. Biochemical Dopamine Terminal Model (SNc terminal) 
The biochemical DA terminal of SNc in the proposed LIT model was adapted from (Muddapu 
and Chakravarthy, 2020). The biochemical model of DA terminal consists of DA turnover 
processes, energy metabolism, and molecular pathways involved in PD pathology. The 
terminal is divided into two compartments, namely intracellular (cytoplasmic and vesicular) 
and extracellular compartments. The DA dynamics in the extracellular compartment ([𝐷𝐴𝑒]) 
was modeled as, 
 
𝑑([𝐷𝐴𝑒])
𝑑𝑡
= 𝐽𝑟𝑒𝑙 − 𝐽𝐷𝐴𝑇 − 𝐽𝑒𝑑𝑎
𝑜  (7) 
 
where, 𝐽𝑟𝑒𝑙 represents the flux of calcium-dependent DA release from the DA terminal, 𝐽𝐷𝐴𝑇 
represents the unidirectional flux of DA translocated from the extracellular compartment (ECS) 
into the intracellular compartment (cytosol) via DA plasma membrane transporter (DAT), and 
𝐽𝑒𝑑𝑎
𝑜  represents the outward flux of DA degradation which clears DA from ECS. 
The DA dynamics in the intracellular compartment ([𝐷𝐴𝑖]) was modeled as 
 
𝑑([𝐷𝐴𝑖])
𝑑𝑡
=
𝑑([𝐷𝐴𝑐])
𝑑𝑡
+
𝑑([𝐷𝐴𝑣])
𝑑𝑡
 (8) 
 
where, [𝐷𝐴𝑐] and [𝐷𝐴𝑣] refer to the DA concentrations in the cytosolic and vesicular 
compartments, respectively.  
8 
 
The DA dynamics in the cytosolic compartment ([𝐷𝐴𝑐]) is given by, 
 
𝑑([𝐷𝐴𝑐])
𝑑𝑡
= 𝐽𝐷𝐴𝑇 − 𝐽𝑉𝑀𝐴𝑇 − 𝐽𝑐𝑑𝑎
𝑜 + 𝐽𝑙𝑑𝑜𝑝𝑎 (9) 
 
where,  𝐽𝐷𝐴𝑇 represents the unidirectional flux of DA translocated from ECS into the cytosol 
through DAT, 𝐽𝑉𝑀𝐴𝑇 represents the flux of DA into vesicle through vesicular monoamine 
transporters (VMAT), 𝐽𝑖𝑑𝑎
𝑜  represents the outward flux of DA degradation which clears DA 
from the cytosol, 𝐽𝑙𝑑𝑜𝑝𝑎 represents the flux of synthesized cytosol DA from levodopa which is 
induced by calcium. 
The DA dynamics in the vesicular compartment ([𝐷𝐴𝑣]) is given by, 
 
𝑑([𝐷𝐴𝑣])
𝑑𝑡
= 𝐽𝑉𝑀𝐴𝑇 − 𝐽𝑟𝑒𝑙 (10) 
 
where, 𝐽𝑟𝑒𝑙 represents the flux of calcium-dependent DA release from the DA terminal, 𝐽𝑉𝑀𝐴𝑇 
represents the flux of DA stored into a vesicle. 
Based on the membrane activity, the DA turnover and other molecular processes were 
modulated in the terminal. The modulation of neuronal activity on the terminal was carried on 
by calcium dynamics, where calcium modulates DA synthesis and release. The calcium-
induced synthesis of DA is given as, 
 𝐽𝑙𝑑𝑜𝑝𝑎 = 𝑓([𝐶𝑎𝑖]) (11) 
 
The calcium-induced release of DA is given as, 
 𝐽𝑟𝑒𝑙 = 𝑓([𝐶𝑎𝑖]) (12) 
 
where, [𝐶𝑎𝑖] is the intracellular calcium concentration in the DA terminal. For more details of 
the SNc terminal model, the reader may refer to (Muddapu and Chakravarthy, 2020). 
2.4. Synaptic Connections 
The synaptic connectivity among different neuronal populations was modelled as a standard 
single exponential model of postsynaptic currents (Humphries et al., 2009) as follows:  
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 𝜏𝑅𝑒𝑐𝑒𝑝 ∗
𝑑(ℎ𝑖𝑗
𝑥→𝑦)
𝑑𝑡
= −ℎ𝑖𝑗
𝑥→𝑦 + 𝑆𝑖𝑗
𝑥 (𝑡) (13) 
 
 𝐼𝑖𝑗
𝑥→𝑦(𝑡) = 𝑊𝑥→𝑦 ∗ ℎ𝑖𝑗
𝑥→𝑦(𝑡) ∗ (𝐸𝑅𝑒𝑐𝑒𝑝 − 𝑣𝑖𝑗
𝑦 (𝑡)) (14) 
 
The N-Methyl-D-aspartic Acid (NMDA) current was regulated by voltage-dependent 
magnesium channels which were modelled as, 
 
𝐵𝑖𝑗(𝑣𝑖𝑗) =
1
1 + (
[𝑀𝑔2+]
3.57 ∗ 𝑒
−0.062 ∗ 𝑣
𝑖𝑗
𝑦
(𝑡)
)
 
(15) 
 
where, ℎ𝑖𝑗
𝑥→𝑦
 is the gating variable for the synaptic current from 𝑥 to 𝑦, τ𝑅𝑒𝑐𝑒𝑝 is the decay 
constant for the synaptic receptor, 𝑆𝑖𝑗
𝑥  is the spiking activity of neuron 𝑥 at time 𝑡, 𝑊𝑥→𝑦 is the 
synaptic weight from neuron 𝑥 to 𝑦, 𝑣𝑖𝑗
𝑦
 is the membrane potential of the neuron 𝑦 for the 
neuron at the location (𝑖,  𝑗), E𝑅𝑒𝑐𝑒𝑝 is the receptor-associated synaptic potential (𝑅𝑒𝑐𝑒𝑝 = 
NMDA/AMPA/GABA), and [𝑀𝑔2+] is the magnesium ion concentration. The time constants 
of Gamma-Amino Butyric Acid (GABA), Alpha-amino-3-hydroxy-5-Methyl-4-isoxazole 
Propionic Acid (AMPA) and NMDA in GPe, CTX, MSN, SNc, and STN were chosen from 
(Götz et al., 1997) as given in Supplementary material-2. 
To accommodate extensive axonal arborization of SNc neurons (Bolam and Pissadaki, 
2012), we considered one-to-many projections from SNc soma to SNc terminals 
(Supplementary material-3). The connectivity patterns among different neuronal populations 
were given in Supplementary material-3. 
2.5. Lateral Connections 
The lateral connections in SNc, STN and GPe, were modelled as Gaussian neighborhoods 
(Muddapu et al., 2019), 
 
𝑤𝑖𝑗,𝑝𝑞
𝑚→𝑚 = 𝐴𝑚 ∗ 𝑒
−𝑑𝑖𝑗,𝑝𝑞
2
𝑅𝑚
2
 
(16) 
 
 𝑑𝑖𝑗,𝑝𝑞
2 = (𝑖 − 𝑝)2 + (𝑗 − 𝑞)2 (17) 
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where, 𝑤𝑖𝑗,𝑝𝑞
𝑚→𝑚 is the lateral connection weight of neuron type 𝑚 at the location (𝑖, 𝑗), 𝑑𝑖𝑗,𝑝𝑞 is 
the distance from center neuron (𝑝, 𝑞), 𝑅𝑚 is the variance of Gaussian, 𝐴𝑚 is the strength of 
lateral synapse, 𝑚 = 𝐺𝑃𝑒 𝑜𝑟 𝑆𝑇𝑁 𝑜𝑟 𝑆𝑁𝑐. 
The connections within SNc and GPe populations were considered as inhibitory and 
within STN as excitatory (Muddapu et al., 2019) (Figure 1). No lateral connections were 
considered for both the MSNs and CTX populations. The lateral currents in the STN and GPe 
were modelled similar to equations (13-15) and in the case of SNc which was modelled as, 
 
𝐻∞ =  
1
1 + 𝑒
(
−(𝑣𝑖𝑗
𝑥 −𝜃𝑔−𝜃𝑔
𝐻)
𝜎𝑔
𝐻 )
 
(18) 
 
 
𝑑(𝑠𝑖𝑗
𝑥→𝑦
)
𝑑𝑡
= 𝛼 ∗ (1 − 𝑠𝑖𝑗
𝑥→𝑦
) ∗ 𝐻∞ − 𝛽 ∗ 𝑠𝑖𝑗
𝑥→𝑦
 (19) 
 
 𝐼𝑖𝑗
𝑥→𝑦(𝑡) = 𝑊𝑥→𝑦 ∗ 𝑠𝑖𝑗
𝑥→𝑦
∗ (𝑣𝑖𝑗
𝑦 (𝑡) − 𝐸𝐺𝐴𝐵𝐴) (20) 
 
where, 𝐼𝑖𝑗
𝑥→𝑦
 is the synaptic current from neuron 𝑥 to 𝑦, 𝑊𝑥→𝑦 is the synaptic conductance from 
neuron 𝑥 to 𝑦, 𝑣𝑖𝑗
𝑥  and 𝑣𝑖𝑗
𝑦
 are the membrane potential of the neuron 𝑥 and 𝑦 respectively for 
the neuron at the location (𝑖,  𝑗), 𝐸𝐺𝐴𝐵𝐴 is the GABAergic receptor potential, 𝑠𝑖𝑗
𝑥→𝑦
 is the synaptic 
gating variable for the neuron. The parametric values of 𝛼, 𝛽, 𝜃𝑔, 𝜃𝑔
𝐻, 𝜎𝑔
𝐻 were adapted from 
(Rubin and Terman, 2004) and given in Supplementary material-4. 
2.6. Neuromodulatory Effect on the Neuronal Populations 
The effect of neuromodulators such as DA and substance P (SP) in the proposed LIT model 
was modelled based on (Muddapu et al., 2019) and (Buxton et al., 2017), respectively. 
2.6.1. Dopaminergic modulation: 
DA-modulated lateral connection strength in SNc, STN, and GPe populations. As DA level 
increases, the lateral connection strength in SNc and GPe increases, whereas, in the case of 
STN, it decreases. DA-modulation of lateral connection strength was modelled as, 
 𝐴𝑆𝑇𝑁 = 𝑠𝑚𝑎𝑥
𝑆𝑇𝑁 ∗ 𝑒(−𝑐𝑑𝑠𝑡𝑛 ∗ 𝐷𝐴𝑠(𝑡)) (21) 
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 𝐴𝐺𝑃𝑒 = 𝑠𝑚𝑖𝑛
𝐺𝑃𝑒 ∗ 𝑒(𝑐𝑑𝑔𝑝𝑒 ∗ 𝐷𝐴𝑠
(𝑡))
 (22) 
 
 𝐴𝑆𝑁𝑐 = 𝑠𝑚𝑖𝑛
𝑆𝑁𝑐 ∗ 𝑒(𝑐𝑑𝑠𝑛𝑐 ∗ 𝐷𝐴𝑠(𝑡)) (23) 
 
where, 𝑠𝑚𝑎𝑥
𝑆𝑇𝑁 , 𝑠𝑚𝑖𝑛
𝐺𝑃𝑒, and 𝑠𝑚𝑖𝑛
𝑆𝑁𝑐 are lateral connection strengths at the basal spontaneous activity 
of the population without any external dopaminergic influence in 𝑆𝑇𝑁, 𝐺𝑃𝑒, and 𝑆𝑁𝑐, 
respectively. 𝑐𝑑𝑠𝑡𝑛, 𝑐𝑑𝑔𝑝𝑒, and 𝑐𝑑𝑠𝑛𝑐 were the factors by which DA affects the lateral 
connections in 𝑆𝑇𝑁, 𝐺𝑃𝑒, and 𝑆𝑁𝑐 populations respectively, 𝐷𝐴𝑠(𝑡) is the instantaneous DA 
level, which is the spatial average DA concentration of all the terminals. All parameter values 
are given in Supplementary material-4. 
The post-synaptic effect of DA in SNc, STN and GPe was modelled similar to 
(Muddapu et al., 2019), 
 𝑊𝑥→𝑦 = (1 − 𝑐𝑑2 ∗ 𝐷𝐴𝑠(𝑡)) ∗ 𝑤𝑥→𝑦 (24) 
 
where, 𝑤𝑥→𝑦 is the synaptic weight (𝑆𝑇𝑁 → 𝐺𝑃𝑒, 𝐺𝑃𝑒 → 𝑆𝑇𝑁, 𝑆𝑇𝑁 → 𝑆𝑇𝑁, 𝐺𝑃𝑒 →
𝐺𝑃𝑒, 𝑆𝑇𝑁 → 𝑆𝑁𝑐, 𝑆𝑁𝑐 → 𝑆𝑁𝑐, 𝑀𝑆𝑁 → 𝑆𝑁𝑐), 𝑐𝑑2 is the parameter that affects the post-
synaptic current, 𝐷𝐴𝑠(𝑡) is the instantaneous DA level. 
The effect of DA in the MSN population occurs on both synaptic and intrinsic ion 
channels (Surmeier et al., 2007). The cortical inputs to MSN were modulated by DA as similar 
to (Humphries et al., 2009), 
 𝐼𝐷𝐴
𝑥 (𝑡) = 𝐼𝐶𝑇𝑋→𝑀𝑆𝑁
𝑥 (𝑡) ∗ (1 + (
𝛽𝐷𝐴
𝛼𝐷𝐴
𝑦 ) ∗ 𝐷𝐴𝑠(𝑡)) (25) 
 
where, 𝐼𝐶𝑇𝑋→𝑀𝑆𝑁
𝑥  is the synaptic current from 𝐶𝑇𝑋 to 𝑀𝑆𝑁 (where 𝑥 =  𝑁𝑀𝐷𝐴 𝑜𝑟 𝐴𝑀𝑃𝐴), 
𝐷𝐴𝑠(𝑡) is the instantaneous DA level, 𝛼𝐷𝐴
𝑦
 is the DA effect on 𝑦 neuron (where 𝑦 =  𝐷1 −
𝑀𝑆𝑁 (𝐺𝑆) 𝑜𝑟 𝐷1 − 𝑀𝑆𝑁 (𝐺)), 𝛽𝐷𝐴 was adapted from (Humphries et al., 2009). 
In addition to modulating cortical afferent connections, DA also has effects on the 
intrinsic ion channels (Humphries et al., 2009) which was modelled in Izhikevich neuronal 
model as, 
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 𝑣𝑟
𝐷𝐴 = 𝑣𝑟
𝑀𝑆𝑁 ∗ (1 + 𝐾𝑀𝑆𝑁 ∗ (
𝐷𝐴𝑠(𝑡)
𝛼𝐷𝐴
𝑦 )) (26) 
 
 𝑑𝑚𝑠𝑛
𝐷𝐴 = 𝑑𝑚𝑠𝑛 ∗ (1 − 𝐿
𝑀𝑆𝑁 ∗ (
𝐷𝐴𝑠(𝑡)
𝛼𝐷𝐴
𝑦 )) (27) 
 
where, 𝑣𝑟
𝐷𝐴 and 𝑑𝑚𝑠𝑛
𝐷𝐴  are the DA-modulated resting potential and after-spike reset value of 
𝑀𝑆𝑁 respectively, 𝑣𝑟
𝑀𝑆𝑁, and 𝑑𝑚𝑠𝑛 are the resting potentials and after-spike reset value of 
𝑀𝑆𝑁 respectively, 𝐷𝐴𝑠(𝑡) is the instantaneous DA level; 𝛼𝐷𝐴
𝑦
 is the DA effect on 𝑦 neuron 
(where 𝑦 =  𝐷1 − 𝑀𝑆𝑁 (𝐺𝑆) 𝑜𝑟 𝐷1 − 𝑀𝑆𝑁 (𝐺)), 𝐾𝑀𝑆𝑁 and 𝐿𝑀𝑆𝑁 were adapted from 
(Humphries et al., 2009). 
2.6.2. Substance P modulation: 
SP modulates excitatory afferent connections of SNc (soma) and D1 MSN (G) in the proposed 
LIT model (Figure 1). It was observed that SP modulates the glutamatergic afferents of MSNs 
directly (Blomeley and Bracci, 2008) or indirectly (Blomeley et al., 2009) by co-release of SP 
by GABAergic D1 MSNs (Buxton et al., 2017; Reiner et al., 2010). In the proposed LIT model, 
we modelled SP-modulation of glutamatergic afferents of the D1 MSN (G) population by the 
D1 MSN (GS) population similar to (Buxton et al., 2017). It was observed that SP and 
tachykinin NK1 receptor (NK1-R) are highly expressed within the SNc (Lessard and Pickel, 
2005; Mantyh et al., 1984; Ribeiro-da-Silva and Hökfelt, 2000; Sutoo et al., 1999; Thornton 
and Vink, 2015). SP-containing striatal neurons project to dopaminergic neurons where SP 
potentiates the release of striatal DA (Brimblecombe and Cragg, 2015; Thornton and Vink, 
2015). It was reported that DA-dependent decrease in SP levels was observed in the basal 
ganglia regions (Sivam, 1991; Thornton et al., 2010; Thornton and Vink, 2015). Therefore, 
there exists a feedback regulation between DA and SP, which helps in maintaining DA 
homeostasis (Thornton et al., 2010; Thornton and Vink, 2015). In the proposed LIT model, we 
assumed that SP modulates STN glutamatergic inputs to SNc such that increased SP levels lead 
to excitation of SNc, which, in turn, enhances striatal DA level, modelled similar to (Buxton et 
al., 2017). Also, we incorporated SP-DA feedback regulation (SDFR) in SP-modulation in the 
proposed LIT model. The SP-modulation of glutamatergic inputs to D1 MSN (G) and SNc 
along with SDFR was given as, 
 𝐼𝑖𝑗
𝑥→𝑦(𝑡) = 𝑊𝑥→𝑦 ∗ ℎ𝑖𝑗
𝑥→𝑦(𝑡) ∗ 𝑁𝑆𝑃 ∗ 𝑆𝐷𝐹𝑅 ∗ (𝑣𝑖𝑗
𝑦 (𝑡) − 𝐸𝑅𝑒𝑐𝑒𝑝) (28) 
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 𝑁𝑆𝑃 = (1 + 𝑤𝑠𝑝 ∗ 𝑁𝑖𝑗
𝑠𝑝
(𝑡 − 𝜏𝑑
𝑠𝑝
)) (29) 
 
 𝑁𝑖𝑗
𝑠𝑝(𝑡) = 𝛽𝑠𝑝 ∗ [1 − 𝑒
(
−𝐴𝑖𝑗
𝑠𝑝(𝑡)
𝜆𝑠𝑝
)
𝑏𝑠𝑝
] (30) 
 
 𝐴𝑖𝑗
𝑠𝑝(𝑡) = [𝑒
(
−𝑆𝑖𝑗
𝑥 (𝑡)
𝜏𝑓
𝑠𝑝 )
− 𝑒
(
−𝑆𝑖𝑗
𝑥 (𝑡)
𝜏𝑟
𝑠𝑝 )
] (31) 
 
 𝑆𝐷𝐹𝑅 = (1 − 𝐷𝐴𝑠(𝑡)) (32) 
 
where, ℎ𝑖𝑗
𝑥→𝑦
 is the gating variable for the synaptic current from 𝑥 to 𝑦, 𝑊𝑥→𝑦 is the synaptic 
weight from neuron 𝑥 to 𝑦, 𝑆𝑖𝑗
𝑥  is the spiking activity of neuron 𝑥 at time 𝑡, 𝑣𝑖𝑗
𝑦
 is the membrane 
potential of the neuron 𝑦 for the neuron at the location (𝑖,  𝑗), E𝑅𝑒𝑐𝑒𝑝 is the receptor-associated 
synaptic potential (𝑅𝑒𝑐𝑒𝑝 = NMDA/AMPA), 𝜏𝑑
𝑠𝑝
 is the fixed time delay between MSN activity 
and the onset of neuropeptide effect, 𝛽𝑠𝑝 is the gain factor, 𝑁𝑖𝑗
𝑠𝑝
 is the modulatory effect of SP, 
𝑤𝑠𝑝 is the influence of SP on 𝑤𝑆𝑇𝑁→𝑆𝑁𝑐, 𝐴𝑖𝑗
𝑠𝑝
 is the amplitude of SP released which is induced by 
spiking activity (𝑆𝑖𝑗
𝑥 ), 𝐷𝐴𝑠(𝑡) is the instantaneous DA level, 𝑏𝑠𝑝 and 𝜆𝑠𝑝 were adapted from 
(Buxton et al., 2017) and given in Supplementary material-4. 
2.7. Total Synaptic Current Received by Each Neuronal Type 
2.7.1. SNc: 
The total synaptic current received by a 𝑆𝑁𝑐 neuron at the lattice position (𝑖, 𝑗) is the 
summation of the glutamatergic input from the 𝑆𝑇𝑁 neurons, considering both 𝑁𝑀𝐷𝐴 and 
𝐴𝑀𝑃𝐴 receptor activation, comprising the GABAergic inputs from the 𝐷1 − 𝑀𝑆𝑁 (𝐺𝑆) and 
𝐷1 − 𝑀𝑆𝑁 (𝐺) neurons and lateral GABAergic current from other 𝑆𝑁𝑐 neurons. 
 
𝐼𝑖𝑗
𝑆𝑁𝑐𝑠𝑦𝑛 = 𝐹𝑆𝑇𝑁→𝑆𝑁𝑐 ∗ (𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝑆𝑁𝑐 +  𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝑆𝑁𝑐)
+ (𝐹𝐷1−𝑀𝑆𝑁 (𝐺)→𝑆𝑁𝑐 ∗ 𝐼𝑖𝑗
𝐷1−𝑀𝑆𝑁(𝐺)→𝑆𝑁𝑐)
+ (𝐹𝐷1−𝑀𝑆𝑁 (𝐺𝑆)→𝑆𝑁𝑐 ∗ 𝐼𝑖𝑗
𝐷1−𝑀𝑆𝑁(𝐺𝑆)→𝑆𝑁𝑐
) + 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴𝑙𝑎𝑡 
(33) 
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where, 𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝑆𝑁𝑐 and 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝑆𝑁𝑐 are the glutamatergic currents corresponding to  𝑁𝑀𝐷𝐴 and 
𝐴𝑀𝑃𝐴 receptors activation respectively; 𝐼𝑖𝑗
𝐷1−𝑀𝑆𝑁(𝐺)→𝑆𝑁𝑐
 and 𝐼𝑖𝑗
𝐷1−𝑀𝑆𝑁(𝐺𝑆)→𝑆𝑁𝑐
are the 
GABAergic inputs from the 𝐷1 − 𝑀𝑆𝑁 (𝐺) and 𝐷1 − 𝑀𝑆𝑁 (𝐺𝑆) neurons respectively; 
𝐼𝑖𝑗
𝐺𝐴𝐵𝐴𝑙𝑎𝑡 is the lateral GABAergic current from other 𝑆𝑁𝑐 neurons;  
𝐹𝑆𝑇𝑁→𝑆𝑁𝑐 is the scaling factor for the glutamatergic current from 𝑆𝑇𝑁 neuron; 𝐹𝐷1−𝑀𝑆𝑁 (𝐺)→𝑆𝑁𝑐 
is the scaling factor for the GABAergic current from 𝐷1 − 𝑀𝑆𝑁 (𝐺) neuron; 𝐹𝐷1−𝑀𝑆𝑁 (𝐺𝑆)→𝑆𝑁𝑐 
is the scaling factor for the GABAergic current from 𝐷1 − 𝑀𝑆𝑁 (𝐺𝑆) neuron. 
2.7.2. GPe: 
The total synaptic current received by a 𝐺𝑃𝑒 neuron at the lattice position (𝑖, 𝑗) is the 
summation of the glutamatergic input from the 𝑆𝑇𝑁 neurons considering both 𝑁𝑀𝐷𝐴 and 
𝐴𝑀𝑃𝐴 receptors activation and the lateral GABAergic current from other 𝐺𝑃𝑒 neurons. 
 𝐼𝑖𝑗
𝐺𝑃𝑒𝑠𝑦𝑛 = 𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝐺𝑃𝑒 + 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝐺𝑃𝑒 + 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴𝑙𝑎𝑡 (34) 
 
where, 𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝐺𝑃𝑒 and  𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝐺𝑃𝑒 are the glutamatergic currents from 𝑆𝑇𝑁 neuron 
considering both 𝑁𝑀𝐷𝐴 and 𝐴𝑀𝑃𝐴 receptors activation respectively; 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴𝑙𝑎𝑡 is the lateral 
GABAergic current from other 𝐺𝑃𝑒 neurons. 
2.7.3. STN: 
The total synaptic current received by a 𝑆𝑇𝑁 neuron at the lattice position (𝑖, 𝑗) is the 
summation of the GABAergic input from the 𝐺𝑃𝑒 neurons and the lateral glutamatergic input 
from other 𝑆𝑇𝑁 neurons considering both 𝑁𝑀𝐷𝐴 and 𝐴𝑀𝑃𝐴 receptors activation. 
 𝐼𝑖𝑗
𝑆𝑇𝑁𝑠𝑦𝑛 = 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴→𝑆𝑇𝑁 + 𝐼𝑖𝑗
𝑁𝑀𝐷𝐴𝑙𝑎𝑡 + 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴𝑙𝑎𝑡 (35) 
 
where, 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴→𝑆𝑇𝑁 is the GABAergic current from 𝐺𝑃𝑒 neuron; 𝐼𝑖𝑗
𝑁𝑀𝐷𝐴𝑙𝑎𝑡 and 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴𝑙𝑎𝑡 are the 
lateral glutamatergic current from other 𝑆𝑇𝑁 neurons considering both 𝑁𝑀𝐷𝐴 and 𝐴𝑀𝑃𝐴 
receptors activation, respectively. 
2.7.4. D1-MSN (GS): 
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The total synaptic current received by a 𝐷1 − 𝑀𝑆𝑁 (𝐺𝑆) neuron at the lattice position (𝑖, 𝑗) is 
the summation of the GABAergic input from the 𝐷1 − 𝑀𝑆𝑁 (𝐺) neurons and the 
glutamatergic input from 𝐶𝑇𝑋 neurons considering both 𝑁𝑀𝐷𝐴 and 𝐴𝑀𝑃𝐴 receptors 
activation. 
 
𝐼𝑖𝑗
𝐷1−𝑀𝑆𝑁(𝐺𝑆)𝑠𝑦𝑛
= 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴→𝐷1−𝑀𝑆𝑁(𝐺𝑆)
+ 𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝐷1−𝑀𝑆𝑁(𝐺𝑆)
+ 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝐷1−𝑀𝑆𝑁(𝐺𝑆)
 
(36) 
 
where, 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴→𝐷1−𝑀𝑆𝑁(𝐺𝑆)
 is the GABAergic current from 𝐷1 − 𝑀𝑆𝑁(𝐺) neuron, 
𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝐷1−𝑀𝑆𝑁(𝐺𝑆)
, and 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝐷1−𝑀𝑆𝑁(𝐺𝑆)
 are the glutamatergic current from 𝐶𝑇𝑋 neurons 
considering both 𝑁𝑀𝐷𝐴 and 𝐴𝑀𝑃𝐴 receptors activation, respectively. 
2.7.5. D1-MSN (G): 
The total synaptic current received by a 𝐷1 − 𝑀𝑆𝑁 (𝐺) neuron at the lattice position (𝑖, 𝑗) is 
the summation of the GABAergic input from the 𝐷1 − 𝑀𝑆𝑁 (𝐺𝑆) neurons and the 
glutamatergic input from 𝐶𝑇𝑋 neurons considering both 𝑁𝑀𝐷𝐴 and 𝐴𝑀𝑃𝐴 receptor 
activation. 
 
𝐼𝑖𝑗
𝐷1−𝑀𝑆𝑁(𝐺)𝑠𝑦𝑛
= 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴→𝐷1−𝑀𝑆𝑁(𝐺)
+ 𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝐷1−𝑀𝑆𝑁(𝐺)
+ 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝐷1−𝑀𝑆𝑁(𝐺)
 
(37) 
 
where, 𝐼𝑖𝑗
𝐺𝐴𝐵𝐴→𝐷1−𝑀𝑆𝑁(𝐺)
 is the GABAergic current from 𝐷1 − 𝑀𝑆𝑁(𝐺𝑆) neuron, 
𝐼𝑖𝑗
𝑁𝑀𝐷𝐴→𝐷1−𝑀𝑆𝑁(𝐺)
, and 𝐼𝑖𝑗
𝐴𝑀𝑃𝐴→𝐷1−𝑀𝑆𝑁(𝐺)
 are the glutamatergic current from 𝐶𝑇𝑋 neurons 
considering both 𝑁𝑀𝐷𝐴 and 𝐴𝑀𝑃𝐴 receptors activation, respectively. 
2.8. Neurodegeneration of SNc neurons 
Calcium plays a dual role in living organisms as a survival factor or a ruthless killer (Orrenius 
et al., 2003). For the survival of neurons, minimal (physiological) levels of glutamate 
stimulation are required. Under normal conditions, calcium concentration within a cell is 
tightly regulated by pumps, transporters, calcium-binding proteins, endoplasmic reticulum 
(ER) and mitochondria (Surmeier et al., 2011; Wojda et al., 2008). Due to prolonged calcium 
influx driven by excitotoxicity, the calcium homeostasis within the cell is disturbed, which 
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results in cellular imbalance, leading to activation of apoptotic pathways (Bano and 
Ankarcrona, 2018).  The SNc soma undergoes degeneration when calcium builds up inside the 
cell becomes high, resulting in calcium loading inside ER and mitochondria, which leads to 
ER-stress-induced and mitochondrial-induced apoptosis respectively (Malhotra and Kaufman, 
2011). In the proposed LIT model, we incorporate a mechanism of programmed cell death, 
whereby a SNc neuron under high stress (high calcium levels) kills itself. The stress in a given 
SNc neuron was observed by monitoring the intracellular calcium concentrations in the 
cytoplasm, ER, and mitochondria. 
The SNc neuron undergoes ER-stress-induced apoptosis when calcium levels in ER cross a 
certain threshold (𝐸𝑅𝑡ℎ𝑟𝑒𝑠). Under such conditions, the particular SNc neuron gets eliminated 
as follows, 
 
 𝑖𝑓    𝐶𝑎𝑖𝑗
𝐸𝑅(𝑡) >  𝐸𝑅𝑡ℎ𝑟𝑒𝑠,      𝑡ℎ𝑒𝑛   𝑣𝑖𝑗
𝑆𝑁𝑐(𝑡) = 0 (38) 
 
where, 𝐶𝑎𝑖𝑗
𝐸𝑅 is the calcium concentration in the ER, 𝐸𝑅𝑡ℎ𝑟𝑒𝑠 is the calcium concentration 
threshold after which ER-stress induced apoptosis gets initiated, 𝑣𝑖𝑗
𝑆𝑁𝑐 is the membrane voltage 
of neuron at the lattice position (𝑖, 𝑗). 
The SNc neuron undergoes mitochondria-induced apoptosis when calcium levels in 
mitochondria cross a certain threshold (𝑀𝑇𝑡ℎ𝑟𝑒𝑠). Then that particular SNc neuron will be 
eliminated as follows, 
 
 𝑖𝑓    𝐶𝑎𝑖𝑗
𝑀𝑇(𝑡) >  𝑀𝑇𝑡ℎ𝑟𝑒𝑠,      𝑡ℎ𝑒𝑛   𝑣𝑖𝑗
𝑆𝑁𝑐(𝑡) = 0 (39) 
 
where, 𝐶𝑎𝑖𝑗
𝑀𝑇 is the calcium concentration in mitochondria, 𝑀𝑇𝑡ℎ𝑟𝑒𝑠 is the calcium 
concentration threshold after which mitochondria-induced apoptosis gets initiated, 𝑣𝑖𝑗
𝑆𝑁𝑐 is the 
membrane voltage of neuron at the lattice position (𝑖, 𝑗). 
 When calcium concentration in ER crosses a certain threshold, there is an efflux of 
excess calcium from ER out into cytoplasm, which in turn activates calpain, resulting in 
activation of proapoptotic factors through cytochrome-c independent apoptotic pathway. 
Similarly, when calcium concentration in MT crosses a certain threshold, excess calcium in 
MT results in the formation of mitochondrial transition pores (MTPs). Proapoptotic 
cytochrome-c released from MT through MTPs, which triggers cytochrome-c dependent 
apoptosis. In the proposed modeling study, when the apoptotic signal gets activated from either 
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of the pathways in a particular neuron, we formulate an approach wherein that particular neuron 
was eliminated by making 𝑣𝑖𝑗
𝑆𝑁𝑐(𝑡) = 0 from the time 𝑡 till the end of the simulation. 
 
2.9. Terminal degeneration of SNc neurons 
DA is the primary contributor to the oxidative stress in the neuron (Lotharius et al., 2005; Luo 
and Roth, 2000; Miyazaki and Asanuma, 2008). To evade oxidative stress, SNc neurons tightly 
regulate the DA turnover processes (Guo et al., 2018). It was suggested that methamphetamine-
induced dopaminergic nerve terminal loss (Ares-Santos et al., 2014; Cadet et al., 2003; Ricaurte 
et al., 1982, 1984) is precipitated by oxidative stress (De Vito and Wagner, 1989) by enhancing 
cytoplasmic DA levels (Larsen et al., 2002; Mark et al., 2004). In the proposed LIT model, the 
oxidative stress in the SNc terminals was observed by monitoring intracellular reactive oxygen 
species (ROS) concentration. The SNc terminal is eliminated when ROS levels in the terminal 
cross certain threshold (𝑅𝑂𝑆𝑡ℎ𝑟𝑒𝑠) as follows, 
 𝑖𝑓    𝑅𝑂𝑆𝑖𝑗
𝑇 (𝑡) >  𝑅𝑂𝑆𝑡ℎ𝑟𝑒𝑠,      𝑡ℎ𝑒𝑛   𝐶𝑎𝑖𝑗
𝑇 (𝑡) = 0 (40) 
 
where, 𝑅𝑂𝑆𝑖𝑗
𝑇  is the ROS concentration in the SNc terminal, 𝑅𝑂𝑆𝑡ℎ𝑟𝑒𝑠 is the ROS concentration 
threshold above which oxidative stress-induced terminal degeneration gets initiated; 𝐶𝑎𝑖𝑗
𝑇  is the 
calcium concentration of the SNc terminal at the lattice position (𝑖, 𝑗). 
 When ROS level crosses a certain threshold, excess ROS triggers degeneration of the 
terminal. In the proposed modeling study, when ROS level crosses the threshold in a particular 
terminal, we formulate an approach wherein that particular terminal was eliminated by making 
𝐶𝑎𝑖𝑗
𝑇 (𝑡) = 0 from the time 𝑡 till the end of the simulation since calcium plays an important role 
in terminal functioning. 
 
2.10. Neuroprotective Strategies 
2.10.1. Levodopa Therapy 
To alleviate PD symptoms, the most potent drug, LDOPA, a precursor of DA, is typically 
administrated (Jankovic and Aguilar, 2008). During medication, serum LDOPA is taken up 
from the blood into the extracellular fluid by aromatic L-amino acid transporter by competing 
with other amino acids (Camargo et al., 2014; Figura et al., 2018). L-DOPA, thus absorbed 
into the bloodstream, later enters SNc terminals and gets converted to DA by aromatic L-amino 
acid decarboxylase (Khor and Hsu, 2007). In the proposed LIT model, serum LDOPA uptake 
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into SNc terminal from the blood was modelled as a single step along with competition with 
other amino acids such as tyrosine and tryptophan (Porenta and Riederer, 1982). It was 
represented using the Michaelis-Menten equation (Chou, 1976) where serum LDOPA 
competes with serum tyrosine and serum tryptophan for transporter (Reed et al., 2012) as given 
below:  
 
𝑉𝑡𝑟𝑎𝑛𝑠 =
𝑉𝑡𝑟𝑎𝑛𝑠
𝑚𝑎𝑥 ∗ [𝐿𝐷𝑂𝑃𝐴𝑆]
𝐾𝑚
𝐿𝐷𝑂𝑃𝐴𝑠 ∗ (1 +
[𝑇𝑌𝑅𝑠]
𝐾𝑎
𝑇𝑌𝑅𝑠
+
[𝑇𝑅𝑃𝑠]
𝐾𝑎
𝑇𝑅𝑃𝑠
) + [𝐿𝐷𝑂𝑃𝐴𝑆]
 
(41) 
 
where, 𝑉𝑡𝑟𝑎𝑛𝑠
𝑚𝑎𝑥  is the maximum flux through aromatic L-amino acid transporter, [𝐿𝐷𝑂𝑃𝐴𝑆] is 
the serum LDOPA concentration, 𝐾𝑚
𝐿𝐷𝑂𝑃𝐴𝑠 is the concentration of [𝐿𝐷𝑂𝑃𝐴𝑆] at which velocity 
of the transporter attained half of the maximal velocity, [𝑇𝑌𝑅𝑠] is the serum tyrosine 
concentration, [𝑇𝑅𝑃𝑠] is the serum tryptophan concentration. 𝐾𝑎
𝑇𝑌𝑅𝑠 is the affinity constant for 
[𝑇𝑌𝑅𝑠], 𝐾𝑎
𝑇𝑅𝑃𝑠 is the affinity constant for [𝑇𝑅𝑃𝑠]. 
LDOPA therapy was implemented in the proposed LIT model by the following 
criterion, 
 [𝐿𝐷𝑂𝑃𝐴𝑠](𝑁𝑠𝑐
𝑧 , 𝑡) = {
0, 𝑁𝑠𝑐
𝑧 (𝑡) > 𝑇𝑙
𝑧
[𝐿𝐷𝑂𝑃𝐴𝑠
𝑚𝑒𝑑], 𝑁𝑠𝑐
𝑧 (𝑡) ≤ 𝑇𝑙
𝑧 (42) 
 
 𝑇𝑙
𝑧 = 𝑃𝑧
𝑠𝑛𝑐 − (𝑝𝑐𝑙 ∗ 𝑃𝑧
𝑠𝑛𝑐) (43) 
 
where, [𝐿𝐷𝑂𝑃𝐴𝑠](𝑁𝑠𝑐
𝑧 , 𝑡) is the instantaneous serum [𝐿𝐷𝑂𝑃𝐴] concentration based on the 
number of surviving SNc neurons or terminals at the time (𝑡) (𝑁𝑠𝑐
𝑧 (𝑡)), [𝐿𝐷𝑂𝑃𝐴𝑠
𝑚𝑒𝑑] is the 
serum [𝐿𝐷𝑂𝑃𝐴] concentration during medication, 𝑁𝑠𝑐
𝑧 (𝑡) is the instantaneous number of 
surviving SNc neurons or terminals, 𝑝𝑐𝑙 is the percentage of SNc cell or terminal loss (25 %) 
at which therapeutic intervention was employed (𝑝𝑐𝑙 = 0.25), 𝑇𝑙
𝑧 represents the number of 
surviving SNc cells or terminals at which therapeutic intervention was employed, 𝑃𝑧
𝑠𝑛𝑐 is the 
population size of 𝑧 (𝑧 =  𝑠𝑜𝑚𝑎 𝑜𝑟 𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙). In the present study, the therapeutic 
intervention is given at 25% SNc cell or terminal loss. 
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2.10.2. SP antagonist therapy 
It was reported that SP exacerbated dopaminergic neurodegeneration in mice (Wang et al., 
2014), and therefore administrating SP antagonists creates neuroprotection of dopaminergic 
neurons in PD (Johnson et al., 2017; Thornton and Vink, 2012, 2015). In the proposed LIT 
model, SP antagonist effect was implemented as, 
 𝑤𝑠𝑝𝑎 = 𝑤𝑠𝑝 ∗ 𝛿𝑠𝑝𝑎 (44) 
 
where, 𝑤𝑠𝑝 is the influence of SP on 𝑤𝑆𝑇𝑁→𝑆𝑁𝑐, 𝛿𝑠𝑝𝑎 is the proportion of SP inhibition, 𝑤𝑠𝑝𝑎 is 
the influence of SP on 𝑤𝑆𝑇𝑁→𝑆𝑁𝑐 under SP antagonist therapy. 
The SP antagonist therapy was implemented in the proposed LIT model by the 
following criterion, 
 𝛿𝑠𝑝𝑎(𝑁𝑠𝑐
𝑧 , 𝑡) = {
0, 𝑁𝑠𝑐
𝑧 (𝑡) > 𝑇𝑙
𝑧
𝛿𝑠𝑝𝑎
𝑚𝑒𝑑, 𝑁𝑠𝑐
𝑧 (𝑡) ≤ 𝑇𝑙
𝑧 (45) 
 
where, 𝛿𝑠𝑝𝑎(𝑁𝑠𝑐
𝑧 , 𝑡) is the instantaneous proportion of SP inhibition based on the number of 
surviving SNc neurons or terminals at the time (𝑡) (𝑁𝑠𝑐
𝑧 (𝑡)), 𝛿𝑠𝑝𝑎
𝑚𝑒𝑑 is the proportion of SP 
inhibition during therapy, 𝑁𝑠𝑐
𝑧 (𝑡) is the instantaneous number of surviving SNc neurons or 
terminals, 𝑇𝑙
𝑧 represents the number of surviving SNc cells or terminals at which therapeutic 
intervention was employed (𝑧 =  𝑠𝑜𝑚𝑎 𝑜𝑟 𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙). 
2.10.3. Glutathione therapy 
The impaired DA metabolism causes oxidative stress (ROS), which in turn leads to PD 
pathogenesis (Masato et al., 2019). It was reported that abnormal activity of vesicular 
monoamine transporter 2 (VMAT2) leads to reduced vesicular DA storage and increased 
cytoplasmic DA which results in oxidative stress-induced degeneration of cell bodies (soma) 
and terminals (Caudle et al., 2007; Kariya et al., 2005; Mingazov and Ugryumov, 2019; Pifl et 
al., 2014). It was reported that the glutathione (GSH) administration results in the improvement 
of PD symptoms, but the underlying mechanism is not clear (Hauser et al., 2009; Mischley et 
al., 2017; Zeevalk et al., 2008). We suggest that glutathione administration might result in 
scavenging of ROS, which in turn leads to neuroprotection (Li et al., 2015). In the proposed 
LIT model, glutathione effect was implemented as, 
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 [𝐺𝑆𝐻𝑔𝑠𝑡
𝑧 ] = [𝐺𝑆𝐻𝑧] + [𝐺𝑆𝐻𝑔𝑠
𝑧 ] (46) 
 
where, [𝐺𝑆𝐻𝑔𝑠
𝑧 ] is the GSH concentration under glutathione therapy (𝑧 =
 𝑠𝑜𝑚𝑎 𝑜𝑟 𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙), [𝐺𝑆𝐻𝑧] is the GSH   concentration. 
The glutathione therapy was implemented in the proposed LIT model by the following 
criterion, 
 [𝐺𝑆𝐻𝑔𝑠
𝑧 ](𝑁𝑠𝑐
𝑧 , 𝑡) = {
0, 𝑁𝑠𝑐
𝑧 (𝑡) > 𝑇𝑙
𝑧
[𝐺𝑆𝐻𝑚𝑒𝑑
𝑧 ], 𝑁𝑠𝑐
𝑧 (𝑡) ≤ 𝑇𝑙
𝑧 (47) 
 
where, [𝐺𝑆𝐻𝑔𝑠
𝑧 ](𝑁𝑠𝑐
𝑧 , 𝑡) is the instantaneous [𝐺𝑆𝐻] therapy based on the number of surviving 
SNc neurons or terminals at the time (𝑡) (𝑁𝑠𝑐
𝑧 (𝑡)), 𝑁𝑠𝑐
𝑧 (𝑡) is the instantaneous number of 
surviving SNc neurons or terminals, [𝐺𝑆𝐻𝑚𝑒𝑑
𝑧 ] is the [𝐺𝑆𝐻] concentration dosage under 𝐺𝑆𝐻 
therapy, 𝑇𝑙
𝑧 represents the number of surviving SNc cells or terminals at which therapeutic 
intervention was employed (𝑧 =  𝑠𝑜𝑚𝑎 𝑜𝑟 𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙). 
 
3. RESULTS 
We investigate the Izhikevich models of the neurons of CTX, MSN, GPe, and STN, which 
were chosen from the literature (Humphries et al., 2009; Mandali et al., 2015; Michmizos and 
Nikita, 2011) for their characteristic firing pattern and other biological properties (Figure 2). 
Along with the above Izhikevich neuronal models, we also investigate the biophysical neuronal 
model of SNc for its characteristic responses (Figure 3). Next, we explored the effect of DA 
and SP on the network of MSN and SNc neurons and compared them with published data 
(Figure 4). 
Then, we show the effect of homogeneous (Figure 5) and heterogeneous (Figure 6) 
energy deficit conditions on the progression of SNc somas and terminals loss. Next, we show 
the effect of extracellular LDOPA on the progression of SNc soma and terminal loss under 
energy deficit conditions (Figure 7A). Finally, we explore various therapeutics such as LDOPA 
(Figure 7B), SP antagonist (Figure 7C), and glutathione (Figure 7D) for their neuroprotective 
effect on the progression of SNc somas and terminals loss under energy deficit conditions. 
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3.1. Characteristic Firing Response of Different Neuronal Types 
The response of a single neuronal model of five different neuronal types involved in the 
proposed LIT model for different external applied currents is shown in Figure 2. The basal 
firing frequencies of the different neuronal types were matched with experimentally observed 
firing (Tripathy et al., 2014) by adjusting 𝐼𝑖𝑗
𝑥  parameter given in Supplementary material-2. 
The pyramidal neurons in the cortex are broadly classified into three types, namely 
regular spiking (RS), intrinsic (inactivating) bursting, and non-inactivating bursting neurons. 
The regular spiking neurons further subdivided into fast-adapting and slow-adapting types of 
neurons (Degenetais, 2002). The time-averaged firing rate of all neuronal types varies widely, 
ranging from < 1 𝐻𝑧 up to several tens of hertz (Griffith and Horn, 1966; Koch and Fuster, 
1989). The spontaneous firing rates of all pyramidal cortical neuronal types are as follows: fast-
adapting RS (0.62 ± 0.75 𝐻𝑧), slow-adapting RS (0.90 ± 1.23 𝐻𝑧), intrinsic bursting 
(3.1 ± 2.6 𝐻𝑧) and non-inactivating bursting (2.8 ± 3.2 𝐻𝑧) (Degenetais, 2002). In the 
proposed LIT model, we adjust 𝐼𝑖𝑗
𝑥  value such that the combined spontaneous and stimulus-
driven firing rate of the pyramidal cortical neuron falls in the range of 10 − 15 𝐻𝑧 (Figure 2A). 
The medium spiny neurons in the striatum broadly classified into two types based on 
the type of DA receptor present, namely D1 and D2-types. In the proposed LIT model, we 
consider only D1-type MSNs because they only project GABAergic inputs to SNc neurons 
(Gerfen, 1985). The spontaneous firing rate of MSN was observed experimentally to be in the 
range of 0.6 − 16.1 𝐻𝑧 (Mahon et al., 2006; Pitcher et al., 2007). In the proposed LIT model, 
we adjust  𝐼𝑖𝑗
𝑥  value such that the combined spontaneous and cortical-driven firing rate of MSN 
falls in the range of 10 − 20 𝐻𝑧 (Figure 2B). 
The STN neurons exhibit two distinct types of firing patterns experimentally: tonic 
pacemaking firing and phasic high-frequency bursting (Allers et al., 2003; Beurrier et al., 
1999). The spontaneous firing rate of STN neurons was observed experimentally to be in the 
range of 6 − 30 𝐻𝑧 (Allers et al., 2003; Lindahl et al., 2013). In the proposed LIT model, we 
adjust  𝐼𝑖𝑗
𝑥  value such that the STN spontaneous firing rate is ~ 13 𝐻𝑧 (Figure 2D). 
The GPe neurons exhibit an atypical type of firing pattern where bursts and pauses 
appear aperiodically in a continuous tonic high-frequency firing (Hegeman et al., 2016; Kita 
and Kita, 2011). The spontaneous firing rate of GPe neuron was observed experimentally to be 
in the range of 8 − 60 𝐻𝑧 (Bugaysen et al., 2010; Elias et al., 2008; Lindahl et al., 2013). In 
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the proposed LIT model, we adjusted 𝐼𝑖𝑗
𝑥  value such that the GPe spontaneous firing rate was 
~ 30 𝐻𝑧 (Figure 2C). 
 
Figure 2: Characteristic behavior of individual neurons. Characteristic behavior of individual CTX (A), 
MSN (B), GPe (C), and STN (D) neuronal types. CTX, cortex; MSN, medium spiny neuron; GPe, globus 
pallidus externa; STN, subthalamic nucleus, Iext, external current; pA, picoampere; mV, millivolt; sec, 
second. 
The SNc neurons exhibit two distinct types of firing patterns experimentally, namely 
background or low-frequency irregular tonic firing (3 − 8 𝐻𝑧) and bursting or high-frequency 
regular phasic firing (~ 20 𝐻𝑧) (Grace and Bunney, 1984b, 1984a). In the proposed LIT 
model, SNc neurons spontaneously fire with a firing rate of ~ 4 𝐻𝑧 (Figure 3). The calcium 
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concentration inside the SNc neuron during the resting state was ~ 1𝑥10−4 𝑚𝑀, and it rises 
up to 1𝑥10−3 𝑚𝑀 upon arrival of the action potential (Figure 3C) (Ben-Jonathan and Hnasko, 
2001; Dedman and Kaetzel, 1997; Wojda et al., 2008). The dopamine released by SNc neuron 
during tonic spiking was ~ 45 𝑥 10−6 𝑚𝑀, which was in the range of (34 −  48) 𝑥 10−6 𝑚𝑀 
observed experimentally (Figure 3D) (Garris et al., 1997).  Upon injection of depolarizing 
external current (continuous pulse (𝐼𝑒𝑥𝑡 = 25 𝑥 10
−6 𝑝𝐴) and duration (1 𝑠𝑒𝑐)), SNc neuron 
exhibits bursting type of firing which lasts for more than one second after the pulse was 
removed (Figure 2B, positive current), demonstrating the slow-adapting nature of SNc neuron 
due to excess calcium build-up inside the neuron (Figure 3C, positive current) (Kuznetsova et 
al., 2010). During the depolarizing current stimulation, SNc neurons exhibit the property within 
a burst that spikes after an initial spike showed a decrease in amplitude (Figure 3B, positive 
current), which is a characteristic bursting property of SNc neurons (Grace and Bunney, 
1984a). The dopamine concentration released by SNc neuron during phasic bursting peaked at 
~ 118 𝑥 10−6 𝑚𝑀 (Figure 3D, positive current), which is in the range of (90 −
 220) 𝑥 10−6 𝑚𝑀 (Chen and Budygin, 2007). Further increase in depolarizing current 
amplitude increases extracellular DA release exponentially but never exceeds beyond 
1 𝑥 10−3 𝑚𝑀 (not shown) (Gonon, 1988). Upon injection of hyperpolarized external current 
(continuous pulse (𝐼𝑒𝑥𝑡 = −300 𝑥 10
−6 𝑝𝐴) and duration (1 𝑠𝑒𝑐)), SNc neuron exhibits 
quiescent state until stimulation was removed (Figure 3B, negative current). Due to 
hyperpolarized current stimulation, the calcium oscillation in SNc neuron was minimal (Figure 
3C, negative current), which was reflected in the near absence of extracellular DA release 
(Figure 3D, negative current). 
The lateral connections in SNc, STN, and GPe neuronal populations were studied in 
the previous work (Muddapu et al., 2019). No lateral connections were considered in CTX and 
MSN neuronal populations for the simplification of the proposed LIT model. 
3.2. Neuromodulatory Effect of Dopamine on MSN and SNc Neuronal Populations 
In the MSN population, DA affects both synaptic and intrinsic ion channels (Surmeier et al., 
2007). As the DA levels increase, the influence of cortical glutamatergic inputs on D1-type 
MSN increases resulting in monotonously increasing firing frequency (Figure 4A), which was 
consistent with experimental work (Cepeda et al., 1993) and previous modeling studies 
(Humphries et al., 2009). In the MSN population, SP affects synaptic ion channels, especially 
glutamatergic afferents (Blomeley et al., 2009; Blomeley and Bracci, 2008). As the SP levels 
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(or SP scaling factor (𝑊𝑠𝑝)) increases, the influence of cortical glutamatergic inputs on D1-
type MSN increases resulting in monotonously increasing firing frequency (Figure 4B), which 
was similar to experimental (Blomeley and Bracci, 2008) and other modelling studies (Buxton 
et al., 2017). 
 
Figure 3: Characteristic behavior of individual SNc neuron. (A) Applied external current (𝐼𝑒𝑥𝑡), (B) 
Membrane potential oscillations (𝑉𝑠𝑛𝑐), (C) Intracellular calcium oscillations (𝐶𝑎𝑖
2+), (D) Extracellular 
dopamine concentration (𝐷𝐴𝑒). pA, picoampere; mV, millivolt; sec, second; mM, millimolar. 
In the SNc population, DA affects both synaptic and lateral connections (Muddapu et 
al., 2019). As the DA level increases, the influence of synaptic and lateral connection inputs 
on SNc increases resulting in non-monotonously decreasing firing frequency (Figure 4C) 
which was similar to experimental (Ford, 2014; Hebb and Robertson, 1999; Tepper and Lee, 
2007; Vandecasteele et al., 2005) and other modelling studies (Muddapu et al., 2019). In the 
SNc population, SP affects the synaptic ion channels, especially glutamatergic afferents 
(Brimblecombe and Cragg, 2015; Thornton and Vink, 2015). As the SP level (or SP scaling 
factor (𝑊𝑠𝑝)) increases, the influence of STN glutamatergic inputs on SNc increases, resulting 
in monotonously increasing firing frequency (Figure 4D), which was similar to experimental 
studies (Brimblecombe and Cragg, 2015). The effect of DA on STN and GPe neuronal 
populations was simulated in the previous work (Muddapu et al., 2019). 
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Figure 4: Neuromodulatory effects of DA and SP on MSN and SNc neuronal populations. Effect of 
dopamine on MSN (A) and SNc (C) populations. Effect of SP on MSN (B) and SNc (D). MSN, medium 
spiny neuron; DA, dopamine; Freq, frequency; SP, substance P; SNc, substantia nigra pars compacta; 
𝑊𝑠𝑝, scaling factor of SP influence; Hz, hertz. 
3.3. Energy Deficiency Occurring Similarly in SNc Somas and Terminals 
In order to study energy deficiency as the possible root cause of SNc cell loss PD, we simulated 
ischemic conditions by modulating glucose and oxygen inputs in the proposed LIT model. As 
SNc somas and terminals are far from each other, the ischemic condition was implemented in 
two ways: homogeneous (energy deficiency occurs similarly in somas (midbrain) and terminals 
(striatum)) and heterogeneous (energy deficiency occurs differently in somas (midbrain) and 
terminals (striatum)). Homogeneous energy deficiency was implemented by reducing glucose 
and oxygen values by same proportions in both SNc somas and terminals. In the case of 
homogeneous energy deficiency, terminal loss starts with just 10% of somas and terminals in 
energy deficiency (Figure 5A, orange bar). However, soma loss starts at 70% of somas and 
terminals in energy deficiency (Figure 5A, blue bar). To observe the influence of STN on SNc 
soma and terminal loss, the currents from STN to SNc were monitored, which showed higher 
positive currents after 60% of somas and terminals are in energy deficiency (Figure 5B). The 
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higher positive current from STN also results in increased ROS production in both SNc somas 
and terminals (Figure 5C). 
 
Figure 5: The model response under homogeneous energy deficiency. (A) The percentage loss of 
SNc somas and terminals, (B) Average positive current from STN to SNc, (C) Average ROS formation. 
STN, subthalamic nucleus; SNc, substantia nigra pars compacta; ROS, reactive oxygen species; mM, 
millimolar; ED, energy deficiency. 
 
Figure 6: The model response under heterogeneous energy deficiency. (A) The percentage loss of 
SNc somas, (B) The percentage loss of SNc terminals. ED, energy deficiency; SNc, substantia nigra 
pars compacta. 
3.4. Energy Deficiency Occurring Differently in SNc Somas and Terminals 
Heterogeneous energy deficiency was implemented by reducing glucose and oxygen values by 
different proportions in both SNc somas and terminals. In the case of heterogeneous energy 
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deficiency, the loss of somas was observed after 75% of somas are in energy deficiency for all 
energy deficiency levels in terminals (Figure 6A). The soma loss was minimal or non-existent 
when the percentage of somas in energy deficiency was below 75% for all levels of energy 
deficiency in terminals except 100%. In the case when 100% of terminals are in energy 
deficiency, the loss of somas was above 20% for all levels of energy deficiency in somas, and 
maximum loss of somas (~ 45%) was observed when 100% of somas are energy deficiency 
(Figure 6A). The terminal loss observed for all percentages of somas and terminals in energy 
deficiency except 0% of terminals in energy deficiency (Figure 6B). The terminal loss 
increases with an increase in the percentage of terminals in energy deficiency for all 
percentages of somas in energy deficiency (Figure 6B). 
3.5. Effect of Extracellular LDOPA 
In order to study the effect of extracellular (serum) LDOPA on SNc somas and terminal loss 
in energy deficiency (100 % energy deficiency), we have modified extracellular LDOPA 
concentration in the range from 36 𝑥 10−9 𝑚𝑀 to 36 𝑚𝑀 with the multiple of 10x (Figure 
7A). With lower concentrations of extracellular LDOPA ranging from 36 𝑥 10−9 𝑚𝑀 to 
36 𝑥 10−7 𝑚𝑀, a more significant los𝑠 (~ 60%) of SNc somas was observed when compared 
to SNc terminals (~ 40%) (Figure 7A). With higher concentrations of extracellular LDOPA 
ranging from 36 𝑥 10−4 𝑚𝑀 to 36 𝑚𝑀, more of SNc terminal loss (~ 95%) was observed 
when compared to SNc somas (~ 35%) (Figure 7B). At intermediate levels of extracellular 
LDOPA concentrations ranging from 36 𝑥 10−7 𝑚𝑀 to 36 𝑥 10−4 𝑚𝑀, the percentage loss of 
SNc somas and terminals were similar which was in the range of 50 − 60%, and these are the 
extracellular LDOPA concentrations that were observed in previous studies (Cullen and Wong-
Lin, 2015; Khor and Hsu, 2007; Reed et al., 2012). 
3.6. Insights into the Mechanism of LDOPA-Induced Toxicity 
In order to test the hypothesis of LDOPA-induced toxicity, we have administered ranges of 
external LDOPA in the proposed model when the percentage loss of somas or terminals crosses 
25% due to energy deficiency. When external LDOPA concentration (36 𝑥 10−4 𝑚𝑀) 
administered was near basal value, it was observed that the percentage loss of SNc somas and 
terminals was not altered much. When external LDOPA concentration administered was in the 
range from 36 𝑥 10−4 𝑚𝑀 to 36 𝑥 10−3 𝑚𝑀, it was observed that the percentage loss of SNc 
somas and terminals was decreasing. When external LDOPA concentration administered was 
above 36 𝑥 10−3 𝑚𝑀, it was observed that the percentage loss of SNc somas was similar, but 
28 
 
the percentage loss of SNc terminals was higher when external LDOPA concentration was near 
basal value (Figure 7B). 
From simulation results, it was observed that LDOPA indeed induced toxicity in SNc 
cells at higher concentrations, which might be due to excitotoxicity or oxidative stress or both. 
To evade LDOPA toxicity in all stages of LDOPA therapy in the case of PD, we need to 
understand the mechanism behind the toxicity. In order to do so, we co-administered two 
different drugs along with LDOPA, namely SP antagonists and glutathione, which led to target 
overexcitation in SNc somas (by reducing SP-mediated excitatory inputs to SNc) and ROS 
build up in SNc terminals (by scavenging ROS) respectively. When SP antagonists are co-
administered, it was observed that the percentage loss of SNc somas was decreasing with 
increasing inhibition of SP transmission (Figure 7C, blue bar). However, there was a change in 
the percentage loss of SNc terminals (Figure 7C, orange bar). When glutathione was co-
administered, it was observed that the percentage loss of SNc somas and terminals was 
decreasing with increasing glutathione concentration (Figure 7D). 
 
Figure 7: Model response to different therapeutics under energy deficiency. (A) Percentage loss for various 
extracellular LDOPA concentrations, (B) Percentage loss during LDOPA therapy, (C) Percentage loss during SP 
antagonist therapy, (D) Percentage loss during glutathione therapy. All the therapeutic interventions were 
initiated at 25% soma or terminal loss. conc, concentration; LDOPA, levodopa; SP, substance P; mM, millimolar. 
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4. DISCUSSION 
4.1. LIT model 
The goal of this computational study is to develop a model of SNc-striatum, which helps us in 
understanding LDOPA-induced toxicity in SNc neurons under energy deficiency conditions. 
From both homogeneous and heterogeneous energy deficiency results, it suggests that SNc 
(axonal) terminals are more vulnerable to energy imbalance when compared to SNc cell bodies 
(somas) which was observed experimentally, where injury is initiated at axonal terminals 
(Burré et al., 2010; Cheng et al., 2010; Giguère et al., 2019; Wong et al., 2019). The higher 
positive currents from STN might lead to excitotoxic loss of SNc somas (Figure 5A, blue bar), 
and increased ROS production might lead to increased SNc terminal loss (Figure 5A, orange 
bar). DA transporters, which play a crucial role in DA neurotransmission, were depleted more 
in axonal terminals compared to cell bodies in early PD (Fazio et al., 2018). From these studies, 
it can be postulated that pathogenesis starts at axonal terminals, which are more vulnerable to 
energy deficiencies and therefore are ideal sites for developing novel disease-modifying 
therapeutics. 
When lower concentrations of extracellular LDOPA were available, the loss of SNc 
somas was more when compared to SNc terminals (Figure 7A). This might be due to lower 
extracellular DA levels as a result of lower extracellular LDOPA concentrations and lower 
vesicular DA levels (due to reduced packing of DA into vesicles as a result of lower energy 
levels)  causing disinhibition of SNc somas (as result of lesser cortical excitation of MSNs) 
which are already in a low energy state. Due to disinhibition and energy deficiency, SNc somas 
might become overactive, which leads to calcium build-up, resulting in excitotoxic loss of SNc 
somas (Albin and Greenamyre, 1992; Muddapu et al., 2019). When higher concentrations of 
extracellular LDOPA were available, the loss of SNc terminals was more when compared to 
SNc somas (Figure 7A). This might be due to higher cytoplasmic DA levels as a result of higher 
extracellular LDOPA concentrations, lower vesicular packing of DA (due to lower energy 
levels) and LDOPA-induced stimulation of DA metabolism (Mosharov et al., 2009) resulting 
in DA-mediated oxidative stress in the SNc terminals (Farooqui, 2012; Morrison et al., 2012). 
Due to higher DA levels and energy deficiency, DA in SNc terminals causes oxidative stress, 
which leads to SNc terminal loss. At higher concentrations of extracellular LDOPA, loss of 
SNc somas was lower compared to lower concentrations of extracellular LDOPA as a result of 
the restoration of inhibitory tone from MSNs due to higher extracellular DA concentrations. 
The extracellular LDOPA concentration ranging from 36 𝑥 10−7 𝑚𝑀 to 36 𝑥 10−4 𝑚𝑀 was 
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considered as basal extracellular LDOPA concentrations in the proposed LIT model. At these 
values, the percentage loss of SNc somas and terminals was similar, which was observed in 
previous studies (Cullen and Wong-Lin, 2015; Khor and Hsu, 2007; Reed et al., 2012). Our 
model was able to show the significance of basal extracellular LDOPA concentrations, which 
needed to be maintained for normal functioning. 
When external LDOPA concentration administered was in the range from 
36 𝑥 10−4 𝑚𝑀 to 36 𝑥 10−3 𝑚𝑀, it was observed that the percentage loss of SNc somas and 
terminals was decreasing, which suggests the therapeutic benefits of LDOPA therapy in 
altering or halting the progression of the SNc cell loss. When external LDOPA concentration 
administered rated was above this range, the neuroprotective effect of LDOPA therapy 
diminished. From LDOPA+SP antagonist co-administration, it was observed that inhibiting 
excitotoxicity in SNc somas did not decrease SNc terminal loss, which suggests that 
excitotoxicity in SNc somas does not contribute to oxidative stress in SNc terminals in 
LDOPA-induced toxicity. From LDOPA+glutathione co-administration, it was observed that 
inhibiting oxidative stress in SNc terminals did decrease the loss of SNc somas, which suggests 
that oxidative stress in SNc terminals does contribute to excitotoxicity in SNc somas in 
LDOPA-induced toxicity. From these results, we can suggest that adjunct therapies such as 
antioxidants (Betharia et al., 2019; Borah and Mohanakumar, 2010; Carvey et al., 1997; Deng 
et al., 2020; Nikolova et al., 2019; Pardo et al., 1993, 1995; Walkinshaw and Waters, 1995) 
and other potential therapies such as D2 agonists (Asanuma et al., 2003), Glycogen synthase 
kinase 3 inhibitors (Choi and Koh, 2018), calcium-binding protein drugs (Isaacs et al., 1997), 
etc. co-administrated along with LDOPA should be able to evade LDOPA toxicity in all stages 
of PD. 
From the simulation results, it was observed that the LDOPA-induced toxicity in cell 
bodies and axonal terminals of SNc neurons was autoxidation-irrelevant and autoxidation-
relevant, respectively. In the case of cell bodies, excess DA in striatum due to LDOPA therapy 
stimulates glutamatergic cortical inputs to MSNs, which leads to overexcitation of MSNs. The 
overexcited MSNs co-release SP along with GABA onto SNc neurons. SP modulates SNc 
glutamatergic inputs in such a way that it overexcites SNc neurons resulting in excitotoxic 
neuronal loss in SNc. However, in the case of axonal terminals, excess DA in terminals due to 
LDOPA therapy leads to autooxidation of DA. The autoxidation of DA results in the production 
of free radicals, which lead to oxidative stress in SNc axonal terminals resulting in axonal 
synaptic pruning of SNc neurons. The study suggests that LDOPA-induced toxicity occurs by 
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two mechanisms: DA-mediated oxidative stress in axonal terminals of SNc neurons and by 
exacerbating STN-mediated overexcitation in cell bodies of SNc neurons. 
4.2. SNc positive feedback loops – Scope of vulnerability 
 
Figure 8: Positive feedback loops of SNc. SNc, substantia nigra pars compacta; STN, subthalamic nucleus; D1 
MSN(G), D1-type DA receptor-expressing medium spiny neuron (release GABA); D1 MSN(GS), D1-type DA 
receptor-expressing medium spiny neuron (co-release GABA and SP); DA, dopamine; SP, substance P; GLU, 
glutamate; GABA, gamma-aminobutyric acid. Inset, DA-SP feedback. 
In normal conditions, there is no SNc cell or terminal loss where SNc maintains the 
dopaminergic tone on its target regions such as STN, D1-MSN(G), and D1-MSN(GS). In the 
first loop (Figure 8), normal dopaminergic tone to D1-MSN(G) results in inhibition of SNc by 
GABAergic projections. In the second loop (Figure 8), normal dopaminergic tone to D1-
MSN(GS) results in inhibition of SNc by GABA and lesser excitation of SNc by SP due to 
DA-SP feedback (Brimblecombe and Cragg, 2015; Thornton and Vink, 2015). In the third loop 
(Figure 8), normal dopaminergic tone to STN results in lesser excitation of SNc by 
glutamatergic projections (Hassani et al., 1997; Magill et al., 2001; Yang et al., 2016). 
 Under pathological conditions, there is SNc cell or terminal loss where SNc fails to 
maintain the dopaminergic tone in its target regions such as STN, D1-MSN(G), and D1-
MSN(GS). In the first loop (Figure 8), DA deficiency in the striatum causes lesser excitation 
of D1-MSN(G) by cortex, which, by feedback, results in disinhibition of SNc. In other words, 
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initial DA deficiency due to SNc cell loss causes lesser excitation of D1-MSN(G), which in 
turn disinhibits SNc resulting in further SNc cell loss due to excitotoxicity, which acts as 
positive feedback. In the second loop, DA deficiency in the striatum causes lesser excitation of 
D1-MSN(GS) by cortex, which results in disinhibition (through GABA) and further excitation 
(through SP; due to low DA, the effect of SP gets enhanced) of SNc. Thus, the disinhibition of 
SNc happens in a manner similar to the first loop; however, the overexcitation of SNc happens 
due to the DA-SP feedback mechanism, which also acts as positive feedback. In the third loop, 
DA deficiency causes overexcitation of STN, which results in overactivation of SNc. In other 
words, initial DA deficiency due to SNc cell loss causes overexcitation of STN, which in turn 
overexcites SNc, by a positive feedback mechanism, resulting in further SNc cell loss due to 
excitotoxicity. 
 In medication conditions, LDOPA is administrated where dopaminergic tone to SNc 
target regions (STN, D1-MSN(G), D1-MSN(GS)) is restored. If the administrated LDOPA 
dosage goes beyond a certain threshold, overexcited D1-MSN(GS) through the DA-SP 
feedback mechanism makes SNc hyperactive, which in turn results in SNc cell loss due to 
excitotoxicity. Along with SNc cell body loss, SNc terminals also undergo degeneration due to 
excess DA causing oxidative stress. To summarize, LDOPA-induced toxicity in SNc doesn’t 
occur when LDOPA dosage is below the threshold, which results in the survival of remaining 
SNc cells. However, if, LDOPA dosage goes beyond a threshold, from that point onwards, the 
aforementioned runaway effect kicks in, leading to a progressive and irrevocable cell loss in 
SNc. Thus, it is evident that LDOPA might be toxic to SNc neurons under high dosage, which 
triggers a runaway effect resulting in uncontrollable SNc cell loss.  
4.3. Limitations and Future Directions 
Though the proposed model captures the exciting results of LDOPA-induced toxicity, it is not 
without limitations. In the proposed model, for example, the serotonergic system was not 
considered, which takes up LDOPA and contributes to striatal DA levels (Stansley and 
Yamamoto, 2015; Svenningsson et al., 2015) that contribute to LDOPA-induced dyskinesias 
(Carta et al., 2008; Carta and Tronci, 2014). Similarly, interneurons in the striatum were also 
not considered for simplifying the model. 
 In the proposed model, the ischemic condition was implemented by lowering glucose 
and oxygen levels, which can be extended by adding a blood vessel module (Cloutier et al., 
2009) and varying cerebral blood flow to simulate ischemia condition more realistically. In the 
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proposed model, stress was monitored in SNc neurons alone, which can be extended to other 
neuronal types in the model by monitoring stress levels, where intracellular calcium build-up 
can be a stress indicator (Bano and Ankarcrona, 2018). In order to do so, all neuronal types 
should be modelled as conductance-based models where calcium dynamics should be included. 
From our studies, it is shown that LDOPA dosage plays an important role in the progression of 
the disease. The proposed model will be integrated with a behavioural model of cortico-basal 
ganglia circuitry (Muralidharan et al., 2018) to show the effect of LDOPA-induced toxicity at 
the behavioural level and optimize the LDOPA dosage so as to achieve maximum effect with 
a minimal dosage of the drug. 
 We suggest some experimental approaches to validate some of the predictions from our 
modelling study. Under induced progressive energy deficiency conditions in animal models 
(Puginier et al., 2019),  LDOPA administration at moderate levels can also be toxic, which 
needs to be studied by measuring metabolites of DA autoxidation process. In order to study the 
effects of LDOPA-induced toxicity in SNc somas in midbrain and SNc terminals in the 
striatum, similar toxin-induced animal models can be used, where oxidative stress in terminals 
can be examined by monitoring the levels of free radicals and excitotoxicity in somas can be 
examined by monitoring calcium levels (Wong et al., 2019). By co-administering antioxidants 
along with LDOPA in toxin-induced animal models (Betharia et al., 2019; Borah and 
Mohanakumar, 2010; Carvey et al., 1997; Nikolova et al., 2019; Pardo et al., 1993, 1995; 
Walkinshaw and Waters, 1995), the progression of SNc soma and terminal loss can be altered 
along with prolonging the ‘honeymoon period’ of LDOPA therapy (Erro et al., 2016; Holford 
and Nutt, 2008; Stocchi et al., 2010). 
5. CONCLUSIONS 
In conclusion, we believe that the proposed model provides significant insights in 
understanding the mechanisms behind LDOPA-induced toxicity under energy deficiency 
conditions. From simulation results, it was shown that SNc terminals are more vulnerable to 
energy imbalances when compared to SNc somas. The study suggests that LDOPA-induced 
toxicity occurs differently in SNc somas and terminals: in the case of SNc somas, it might be 
due to excitotoxicity caused by STN, and in case of SNc terminals, it might be due to oxidative 
stress caused by dopamine autoxidation. From adjunct therapies, it was clear that co-
administering antioxidants, along with LDOPA, can be neuroprotective. By the 
aforementioned modelling efforts in addition to some earlier ones (Muddapu et al., 2019), we 
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are trying to understand the root cause of PD neurodegeneration as energy deficiency occurring 
at different neural hierarchies: subcellular, cellular and network levels. 
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Table 1: Different population sizes in the proposed LIT model. 
Network type Size (# of nodes) 
SNc (soma) 8 𝑥 8 (64) 
SNc (terminal) 32 𝑥 32 (1024) 
D1-MSN (G) 32 𝑥 32 (1024) 
D1-MSN (GS) 32 𝑥 32 (1024) 
STN 32 𝑥 32 (1024) 
GPe 32 𝑥 32 (1024) 
CTX 32 𝑥 32 (1024) 
 
Table 1: Parameter values used in the proposed model of LIT. 
Parameter(s) STN GPe CTX MSN 
Izhikevich parameters  
𝑎 (𝑚𝑠−1), 
𝑏 (𝑝𝐴. 𝑚𝑉−1), 
𝑐 (𝑚𝑉), 
𝑑 (𝑝𝐴) 
 
𝑎 = 0.005, 
𝑏 = 0.265, 
𝑐 = −65, 
𝑑 = 1.5 
 
𝑎 = 0.1, 
𝑏 = 0.2, 
𝑐 = −65, 
𝑑 = 2 
 
𝑎 = 0.03, 
𝑏 = −2, 
𝑐 = −50, 
𝑑 = 100 
 
𝑎 = 0.01, 
𝑏 = −20, 
𝑐 = −55, 
𝑑 = 91 
External current (𝐼𝑥) 3 𝑝𝐴 4.25 𝑝𝐴 100 𝑝𝐴 0 𝑝𝐴  
Maximum peak of voltage (𝑣𝑝𝑒𝑎𝑘
𝑥 ) 30 𝑚𝑉 30 𝑚𝑉 40 𝑚𝑉 35 𝑚𝑉 
Membrane capacitance (𝐶𝑥) 1 𝜇𝐹 1 𝜇𝐹 100 𝜇𝐹 15.2 𝑝𝐹 
Resting potential (𝑣𝑟
𝑥) - - - −80 𝑚𝑉 
Threshold potential (𝑣𝑡
𝑥) - - - −29.7 𝑚𝑉 
Membrane constant (𝑘𝑥) - - - 1 𝑝𝐴. 𝑚𝑉−1 
Number of laterals (𝑛𝑙𝑎𝑡𝑥) 11 15 - - 
Radius of Gaussian laterals (𝑅𝑥) 1.4 1.6 - - 
Synaptic strength within laterals (𝐴𝑥) 1.3 0.1 - - 
Time decay constant for AMPA (𝜏𝐴𝑀𝑃𝐴) 6 𝑚𝑠 6 𝑚𝑠 6 𝑚𝑠 6 𝑚𝑠 
Time decay constant for NMDA (𝜏𝑁𝑀𝐷𝐴) 160 𝑚𝑠 160 𝑚𝑠 160 𝑚𝑠 160 𝑚𝑠 
Time decay constant for GABA (𝜏𝐺𝐴𝐵𝐴) 4 𝑚𝑠 4 𝑚𝑠 4 𝑚𝑠 4 𝑚𝑠 
Synaptic potential of AMPA receptor 
(𝐸𝐴𝑀𝑃𝐴) 
0 𝑚𝑉 0 𝑚𝑉 0 𝑚𝑉 0 𝑚𝑉 
Synaptic potential of NMDA receptor 
(𝐸𝑁𝑀𝐷𝐴) 
0 𝑚𝑉 0 𝑚𝑉 0 𝑚𝑉 0 𝑚𝑉 
Synaptic potential of GABA receptor 
(𝐸𝐺𝐴𝐵𝐴) 
−60 𝑚𝑉 −60 𝑚𝑉 −60 𝑚𝑉 −60 𝑚𝑉 
Concentration of Magnesium (𝑀𝑔2+) 1 𝑚𝑀 1 𝑚𝑀 1 𝑚𝑀 1 𝑚𝑀 
 
Table 1: Connectivity patterns in the proposed LIT model. 
From – to Pattern (signal) 
SNc (soma) – SNc (terminal) 1 to 16 (Calcium) 
SNc (terminal) – D1-MSN (GS) 20 to 1 (Dopamine) 
SNc (terminal) – D1-MSN (G) 20 to 1 (Dopamine) 
D1-MSN (GS) – D1-MSN (G) 1 to 1 (GABA & SP) 
D1-MSN (G) – D1-MSN (GS) 1 to 1 (GABA) 
D1-MSN (GS) – SNc (soma) 200 to 1 (GABA & SP) 
D1-MSN (G) – SNc (soma) 200 to 1 (GABA) 
STN – GPe 1 to 1 (Glutamate) 
GPe – STN 1 to 1 (GABA) 
STN – SNc (soma) 16 to 1 (Glutamate) 
CTX – D1-MSN (GS) 1 to 1 (Glutamate) 
CTX – D1-MSN (G) 1 to 1 (Glutamate) 
STN – STN Gaussian neighborhoods (Glutamate) 
GPe – GPe Gaussian neighborhoods (GABA) 
SNc – SNc Gaussian neighborhoods (GABA) 
 
Table 1: Parameter values used in the proposed model of LIT. 
Parameter Value Parameter Value 
Number of laterals (𝑛𝑙𝑎𝑡𝑥) 5 𝜃𝑔 20 𝑚𝑉 
Radius of Gaussian laterals (𝑅𝑥) 1.6 𝜃𝑔
𝐻 −57 𝑚𝑉 
Synaptic strength within laterals (𝐴𝑥) 0.1 𝜎𝑔
𝐻 2 𝑚𝑉 
Synaptic conductance (𝑊𝑥→𝑦) 0.01 𝛼 2 𝑚𝑠−1 
Synaptic potential of GABA 
receptor (𝐸𝐺𝐴𝐵𝐴) 
63.45 𝑚𝑉 𝛽 0.08 𝑚𝑠−1 
𝑠𝑚𝑎𝑥
𝑆𝑇𝑁  1.3 𝑐𝑑𝑠𝑡𝑛 4.87 
𝑠𝑚𝑖𝑛
𝐺𝑃𝑒 0.1 𝑐𝑑𝑔𝑝𝑒 7 
𝑠𝑚𝑖𝑛
𝑆𝑁𝑐 1 𝑥10−6 𝑐𝑑𝑠𝑛𝑐 4.6055 
𝑐𝑑2 0.1 𝑤𝑠𝑝 5000 
𝐾𝑀𝑆𝑁 0.0289  𝐿𝑀𝑆𝑁 0.331 
𝛼𝐷𝐴
𝐷1−𝑀𝑆𝑁(𝐺)
 1 𝛼𝐷𝐴
𝐷1−𝑀𝑆𝑁(𝐺𝑆)
 2 
𝑤𝐺𝑃𝑒→𝐺𝑃𝑒 1 𝑤𝑆𝑁𝑐→𝑆𝑁𝑐 0.01 
𝑤𝑆𝑇𝑁→𝐺𝑃𝑒 1 𝑤𝐺𝑃𝑒→𝑆𝑇𝑁 20 
𝑤𝑆𝑇𝑁→𝑆𝑇𝑁 1.3 𝑤𝑆𝑇𝑁→𝑆𝑁𝑐 0.3 
𝑤𝐷1−𝑀𝑆𝑁 (𝐺)→𝑆𝑁𝑐 0.5 𝑤𝐷1−𝑀𝑆𝑁 (𝐺𝑆)→𝑆𝑁𝑐 0.5 
𝑤𝐷1−𝑀𝑆𝑁 (𝐺)→𝐷1−𝑀𝑆𝑁 (𝐺𝑆) 500 𝑤𝐶𝑇𝑋→𝐷1−𝑀𝑆𝑁 (𝐺𝑆) 100 
𝑤𝐶𝑇𝑋→𝐷1−𝑀𝑆𝑁 (𝐺) 100 𝜏𝑑
𝑠𝑝 40 𝑚𝑠 
𝜏𝑓
𝑠𝑝 200 𝑚𝑠 𝜏𝑟
𝑠𝑝
 10 𝑚𝑠 
𝛽𝑠𝑝 0.47 𝜆𝑠𝑝 5.5 
 𝑏𝑠𝑝 2.5 𝐹𝑆𝑇𝑁→𝑆𝑁𝑐 1 𝑥10
−5 
𝐹𝐷1−𝑀𝑆𝑁 (𝐺)→𝑆𝑁𝑐 4.15 𝑥10−6 𝐹𝐷1−𝑀𝑆𝑁 (𝐺𝑆)→𝑆𝑁𝑐 4.15 𝑥10−6 
𝑉𝑡𝑟𝑎𝑛𝑠
𝑚𝑎𝑥  5.11 𝑥10−7 𝑚𝑀. 𝑚𝑠−1 𝐾𝑚
𝐿𝐷𝑂𝑃𝐴𝑠  0.032 𝑚𝑀 
[𝑇𝑌𝑅𝑠] 0.063 𝑚𝑀 𝐾𝑎
𝑇𝑌𝑅𝑠 0.064 𝑚𝑀 
[𝑇𝑅𝑃𝑠] 0.082 𝑚𝑀 𝐾𝑎
𝑇𝑅𝑃𝑠 0.015 𝑚𝑀 
𝑃𝑠𝑜𝑚𝑎
𝑠𝑛𝑐  64 𝑃𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙
𝑠𝑛𝑐  1024 
𝐸𝑅𝑡ℎ𝑟𝑒𝑠 2.15 𝑥10
−3 𝑚𝑀 𝑅𝑂𝑆𝑡ℎ𝑟𝑒𝑠 0.0147 𝑚𝑀 
𝑀𝑇𝑡ℎ𝑟𝑒𝑠 0.0215 𝑚𝑀   
